David Kirn
Founder at 4D MOLECULAR THERAPEUTICS, INC.
Net worth: 34 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Theresa Janke | F | 49 | 11 years | |
| Terry Hermiston | M | - |
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | 5 years |
| Fariborz Kamal | M | 61 | 6 years | |
| Charles Theuer | M | 60 |
The University of California, San Francisco
| 12 years |
| Scott Bizily | M | 52 | 3 years | |
| Noriyuki Kasahara | M | 62 | 2 years | |
| Ian Gardiner | M | - |
University of Oxford
| - |
| John Milligan | M | 63 | 4 years | |
| Jacob Chacko | M | 45 | 5 years | |
| Shawn Tomasello | F | 65 | 4 years | |
| Nancy Miller-Rich | F | 65 | 4 years | |
| Julian Pei | M | - | - | |
| Susannah Gray | F | 63 | 4 years | |
| Robert Kim | M | 63 | 2 years | |
| Bernard J. Taylor | M | 67 |
University of Oxford
| - |
| Uneek Mehra | M | - | 1 years | |
| Jan Tadeusz Czernuszka | M | - |
University of Oxford
| - |
| Won Chul Cho | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Ngaire Woods | F | 62 |
University of Oxford
| 14 years |
| Anil Razdan | M | 75 |
University of Oxford
| - |
| David A. Larson | M | 83 |
The University of California, San Francisco
| 38 years |
| Jinkyun Kim | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Robin Hanson | M | - |
University of Oxford
| - |
| Stephen Pulman | M | - |
University of Oxford
| - |
| Stefan Karl Neubauer | M | - |
University of Oxford
| - |
| Elish Angiolini | F | - |
University of Oxford
| - |
| Mankyu Park | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Stephen Westaby | M | - |
University of Oxford
| - |
| David Kerr | M | - |
University of Oxford
| - |
| Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 years |
| An Song | M | - | 3 years | |
| J. Doyne Farmer | M | 71 |
University of Oxford
| - |
| André Finn | M | - |
University of Oxford
| - |
| Daekyeong Bae | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | 5 years |
| Sheila Barrett | F | - |
University of Oxford
| - |
| Zhan Feng Cui | M | 62 |
University of Oxford
| - |
| David J. Teece | M | 75 |
University of California, Berkeley
| 42 years |
| Jeff Orenstein | M | - |
University of Oxford
| - |
| André S. Hoffmann | M | 65 |
University of Oxford
| - |
| Philip E. Wolfson | M | 79 |
The University of California, San Francisco
| 38 years |
| Andrew Wolff | M | 69 |
The University of California, San Francisco
| 38 years |
| Robin Steele | F | 68 |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Len Blavatnik | M | 66 |
University of Oxford
| - |
| William R. Miller | M | 95 |
University of Oxford
| - |
| James Pennington | M | 81 |
The University of California, San Francisco
| 38 years |
| Ivan M. Lieberburg | M | 74 |
The University of California, San Francisco
| 36 years |
| Crispin Davis | M | 75 |
University of Oxford
| - |
| William Castell | M | 76 |
University of Oxford
| - |
| Lai Kuen Louey | M | 64 |
University of Oxford
| 13 years |
| Soo Min Yeoh | F | 68 |
University of Oxford
| - |
| Patrick Pichette | M | 61 |
University of Oxford
| - |
| Lionel Tarassenko | M | 67 |
University of Oxford
| 27 years |
| Indrajit Wickramasinghe | M | - |
University of Oxford
| - |
| Simon Boddie | M | 64 |
University of Oxford
| 3 years |
| Julie Baddeley | F | 73 |
University of Oxford
| - |
| Alex Hawker | M | - |
University of Oxford
| - |
| Benjamine Reid | M | - |
University of Oxford
| - |
| Nigel Shadbolt | M | 68 |
University of Oxford
| - |
| Geert Linnebank | M | 68 |
University of Oxford
| - |
| Marc K. Hellerstein | M | 72 |
The University of California, San Francisco
| 37 years |
| Marc Feldmann | M | 79 |
University of Oxford
| 13 years |
| Wendy Becker | F | 58 |
University of Oxford
| - |
| John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 years |
| Peter Ratcliffe | M | 69 |
University of Oxford
| - |
| Geoffrey Hale | M | - |
University of Oxford
| - |
| Cheryl Musch | F | - |
University of Oxford
| - |
| Malcolm McCulloch | M | - |
University of Oxford
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Qing Huang | M | 62 |
University of California, Berkeley
| 6 years |
| Paul Jacobs | M | 61 |
University of California, Berkeley
| 9 years |
| Kamal H. Khayat | M | - |
University of California, Berkeley
| 7 years |
| Carl Perez | M | - |
University of California, Berkeley
| 8 years |
| David Schaffer | M | 53 | 9 years | |
| Sung Su Han | M | 72 |
University of California, Berkeley
| 12 years |
| Irving Mintzer | M | - |
University of California, Berkeley
| 13 years |
| Fabio Ignazio Romeo | M | 68 |
University of California, Berkeley
| 4 years |
| Adam Rossman | M | 57 |
University of California, Berkeley
| 6 years |
| Nat Simons | M | - |
University of California, Berkeley
| 10 years |
| Wei-Tek Tsai | M | 64 |
University of California, Berkeley
| 5 years |
| Tami S. Smason | F | - |
University of California, Berkeley
| 8 years |
| Richard G. Wallace | M | - |
University of California, Berkeley
| 7 years |
| Ze Xiang Li | M | 63 |
University of California, Berkeley
| 4 years |
| Pierre Breber | M | 59 |
University of California, Berkeley
| 5 years |
| Ray Salomon | M | 61 |
University of California, Berkeley
| 7 years |
| Bahram Nour-Omid | M | - |
University of California, Berkeley
| 4 years |
| Michael J. Estrada | M | - |
University of California, Berkeley
| 3 years |
| Fu Chieh Hsu | M | - |
University of California, Berkeley
| 3 years |
| Thomas E. Bell | M | 75 |
University of California, Berkeley
| 4 years |
| Andreas C. Cangellaris | M | - |
University of California, Berkeley
| 3 years |
| Jaideep Srivastava | M | - |
University of California, Berkeley
| 4 years |
| Sosale Shankara Sastry | M | 67 |
University of California, Berkeley
| 3 years |
| Mark Schena | M | 60 |
The University of California, San Francisco
University of California, Berkeley
| 8 years |
| Gregory M. Heywood | M | 59 |
University of California, Berkeley
| 12 years |
| Thomas E. Tighe | M | - |
University of California, Berkeley
| 7 years |
| Steve Tighe | M | - |
University of California, Berkeley
| 5 years |
| Michael Cima | M | 64 |
University of California, Berkeley
| 8 years |
| Lisa Suennen | F | 58 |
University of California, Berkeley
| 5 years |
| David Choi | M | - |
University of California, Berkeley
| 5 years |
| Eric Stonestrom | M | 62 |
University of California, Berkeley
| 6 years |
| Tony Yao | M | 51 | - | |
| Fabio Romeo | M | - |
University of California, Berkeley
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 60.00% |
| United Kingdom | 40 | 40.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Kirn
- Personal Network
